Pfizer to Offer $1.5M in Grant Funding to Support BRCA Testi
Industry news | 28 June, 2018 | CACLP
The Association of Community Cancer Centers(ACCC), a cancer care provider advocacy group, announced today that Pfizer willprovide $1.5 million in grant funding to support initiatives integrating BRCAtesting into patient care plans.
The funding, which is being provided underthe Pfizer Independent Grants for Learning and Change program, will provide upto $150,000 to individual grant awardees. It is only available to ACCC-membercancer programs and practices.
"We are pleased to partner with ACCCon this grant program designed to tackle access challenges to BRCA testing,which will hopefully result in breast cancer patients having more informationabout their diagnoses and enable them to make more educated decisions abouttheir care," Julia Perkins Smith, North America medical vice president ofPfizer oncology, said in a statement.
Pfizer is currently developing the PARPinhibitor talazoparib for breast cancer patients with germline BRCA mutations.The drug was recently shown to reduce the risk of disease progression by 46percent versus chemotherapy in a Phase III study.
Press contact
Go back
